SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 688.58+2.0%3:04 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (2824)12/19/2019 11:53:32 AM
From: Miljenko Zuanic2 Recommendations

Recommended By
Biotech Jim
CuttingEdge Bio

   of 3557
 
Interesting CMS data for Eylea/Lucentis for 2018, relative to 2017.

Eylea...spending was almost flat $2.57B v $2.47B (~$100M increase), pts # flat (10K increase), spending /subject/Y flat (~$10.6K).
Similar numbers for Lucentis (2018 v 2017).

Contrary, total US Eylea sale for 2018 was $4.08B v $3.72B ($360M increase) indicating expansion into DME and/or non-Medicare (private insurance) subjects. This trend definitely extended in 2019, and will continue few more years if not longer.

ALL this without ANY price increase, in last 5 years (14-19). Maybe they should start to increase price, to compensate inflations!

CMS # (Medicare) was ~63% of the 2018 US sale for Eylea.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News